Progress in Lung Cancer Screening Adoption
Ce dossier présente deux articles, l'un concernant la prévalence du dépistage des cancers du poumon aux Etats-Unis en 2022 et l'autre examinant l'intérêt d'un parcours coordonné pour améliorer l'accès des sans-abris au dépistage des cancers du poumon par tomographie numérique à faible dose de rayonnement
The National Lung Screening Trial, a landmark randomized clinical trial that demonstrated the efficacy of lung cancer screening with low-dose computed tomography (LDCT), was published more than a decade ago. In the interim, the US Preventive Services Task Force has endorsed lung cancer screening in certain adults, insurance coverage of LDCT has expanded, and a second large randomized clinical trial, the NELSON trial, demonstrated that LDCT can reduce lung cancer mortality. Importantly, annual LDCT screening also carries risks. In a recent observational study, approximately 32% of those screened underwent additional imaging, 3% had invasive testing, and 31% of those who received invasive testing had a complication.
JAMA Internal Medicine , éditorial, 2023